BMRN Pulls The Plug On DMD Drug, LXRX To Face FDA In Nov, TEVA Snubbed

Lexicon Pharmaceuticals Inc.'s (LXRX) New Drug Application for Telotristat etiprate, an oral drug for the treatment of carcinoid syndrome has been granted priority review by the FDA - with a decision scheduled for November 30, 2016.

from RTT - Biotech http://ift.tt/1sKKF91
via IFTTT